Oncosil (ASX:OSL) - CEO, Daniel Kenny
CEO, Daniel Kenny
Source: BellDirect
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Oncosil Medical (OSL) will raise around $5 million from a fully-underwritten entitlement offer, despite falling almost 40 per cent short on subscriptions
  • The company had offered over 56 million new shares at a price of nine cents each — a 19.3 per cent discount to the five-day volume-weighted average price
  • The offer was substantially undersubscribed though, with only around $3.1 million of the target raised from shareholders
  • Underwriter Bell Potter will now either subscribe for, or place the remaining shares which were not taken up under the offer
  • The company says the money raised will drive commercialisation activities across Europe, Asia and the U.S., and fund ongoing clinical trials
  • Oncosil is trading two per cent higher today at 10.2 cents per share

Meditech company Oncosil Medical (OSL) will raise around $5 million from a fully-underwritten entitlement offer, despite falling almost 40 per cent short on subscriptions.

The company had offered over 56 million new shares at a price of nine cents each, which represented a 19.3 per cent discount to the five-day volume-weighted average price (VWAP) to April 28 when the capital raise was first announced.

The offer was substantially undersubscribed though, with only around $3.1 million of the target raised from shareholders.

Underwriter Bell Potter will now either subscribe for or place the remaining 21,628,774 shares, which were not taken up under the offer.

While the company may be somewhat deflated at the lack of interest in the one-for-eleven non-renounceable entitlement offer, it has still reached its fundraising goal of $19 million from the entitlement offer and institutional placement.

The company says the money raised will drive commercialisation activities across Europe, Asia and the U.S., and fund ongoing clinical trials.

Oncosil is trading two per cent higher today at 10.2 cents per share as at 12:05 pm AEST.

OSL by the numbers
More From The Market Herald

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…

Little Green Pharma’s strong half-year performance signals robust Cannabis growth in Europe and Australia

Little Green Pharma (ASX:LGP) released its half-yearly financial report, showing revenue from ordinary cannabis sales is…

4DMedical inks MOU with Philips to expand XV Technology sales in North America

4DMedical (ASX:4DX) has signed a MOU with Philips to expand sales opportunities for its XV Technology…